MIST

$1.04-$0.05 (-4.89%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$140.1M

124M shares

52-week range

$1.00 – $3.06

2% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-4.38

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$5M	+24.3%	$-0.84	$-1.01–$-0.75	—	4
2027	$25M	+366.2%	$-0.96	$-1.26–$-0.74	—	4
2028	$126M	+400.0%	$-0.31	$-0.42–$-0.17	—	2
2029	$221M	+75.5%	$0.15	$0.09–$0.21	6.7×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-0.20	$-0.21	-7.7%
2026-05-13	$0.06	$-0.20	-433.3%
2026-03-20	$-0.18	$-0.16	+11.1%
2025-11-12	$-0.17	$-0.12	+29.4%
2025-08-12	$-0.18	$-0.20	-11.1%
2025-05-14	$-0.19	$-0.31	-63.2%
2025-03-13	$-0.15	$-0.19	-26.7%
2024-11-12	$-0.16

DCF fair valuemodel estimate

Intrinsic value

$0.15

Price

$1.04

Implied downside

-85%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
MISTMilestone Pharmaceuticals Inc.	$1.07	-4.89%	$133M	—
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	$15M	—
CRBPCorbus Pharmaceuticals Holdings, Inc.	$10.08	+3.28%	$187M	—
CRDFCardiff Oncology, Inc.	$0.98	-0.66%	$76M	—
CYBNCybin Inc.	$8.28	+1.22%

Milestone Pharmaceuticals Inc. Common Shares

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

www.milestonepharma.com

Employees: 38
IPO / List date: May 9, 2019
HQ: MONTREAL, A8

Held by traders on TradeandTell

No one on the platform currently holds MIST.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	129,705	$154.3K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded MIST yet.

$MIST chatter on StockTwits

alex pitti@alexpitti4h
$MIST balance sheet projection by me
View on StockTwits ↗
Sloan Kettering@Gooble5h
@BioRich I saw a post awhile ago that Joe took Chelsea Therapeutics to FDA approval with a BO two months later in 2014. Someone suspected that he would want to take a drug to commercialization and $MIST it was. Would have swing traded, long hold now with 19k shares @ $1.38. I see the future paying well, maybe have to hold through 2027 and maybe 2028.
View on StockTwits ↗
alex pitti@alexpitti6h
$MIST I believe milestone will sell $1.5 million in Q3 and $2.75 million in Q4. then they will sell $25 million in 2027. at this rate they will run out of cash by year end especially with the costs of the afib trial. if that's the case milestone will raise capital in mid 2027. the approval in china can give them an extra quarter of runway. there is a scenario where demand picks up and the stock rises to $3 and they issue shares there so there isn't that much dillution. obviously if they tried to raise $50 million now, the stock would fall to 75 cents. they need to show script growth in sepbember. i don't understand why management sees the inflection in q4.
View on StockTwits ↗
The Legendary Mayor@BioRich6h
@Gooble Definitely a learning experience. The issue I have is that as I piece together the previous communications, $MIST should not be in the this spot. I think the thesis was right, the execution was misleading and underwhelming. After the call yesterday, I'm in the take the L category. Maybe something down the line, but I don't think these guys know what they're doing.
View on StockTwits ↗
alex pitti@alexpitti7h
$MIST analysts expect $23.X million in 2027 sales
View on StockTwits ↗
The Legendary Mayor@BioRich8h
$MIST What a disaster. I had to go back and read previous statements from this management team to see if I was delusional...nope, they told us one thing and did another. We stuck up for them, but getting scripts in Q2 was their make or break for me. They not only missed, it was quite frankly embarrassing. Criminal if you compare to what they laid out for us. Also, it doesn't appear anyone actually wants this. Docs writing one script at a time? This SHOULD have been massive. Large unmet need with a novel mechanism to keep people having a medical event self treat without having to go to the ER. This was a winner. Until it wasn't. SP flop on approval should have been a sign. Tutes and analysts must have known the management team were a bunch of side speaking bozos focused more on saying they can get a drug approved than actually do something with hit. Shame on you $MIST>
View on StockTwits ↗
alex pitti@alexpitti9h
i made a new twitter. follow me $MIST https://x.com/alexpitti_abvx
View on StockTwits ↗
Ryan Hemenway@TheYoungGeologist10h
$MIST is there any chance we get some Part D coverage when CMS releases 2027 plan info in September? If we do indeed miss this cycle, do we have to wait all the way for September 2027 in order to get coverage starting Jan 2028, or are there mid year adjustments?
View on StockTwits ↗
Roy Brown@Rawbinhood11h
$MIST My calculation is your a idiot!! We are in 2026, Where do these trolls come from!!!
View on StockTwits ↗
alex pitti@alexpitti12h
my calculation is $MIST will burn $95 million in 2024. what's yours?
View on StockTwits ↗
Newmoves@NewmovesBearish12h
$MIST it’s just that simple. The stock is down 50% year to date investors are not impressed with results so far.
View on StockTwits ↗
Deep BlueCyan@DeepBlueCyan12h
$MIST Let get their survival out of the way first. Their cash can carry them to the second half of 2027. China approval could come soon with potentially up to $107M of milestone payment (no pun intended). Another possibility is a partnership for Europe. In any case, the need to raise money is not immediate. Now, Cardamyst is a paradigm change from patients being cared for by doctors and nurses at ERs or hospitals to caring to themselves at home. Except for episodes of PSVT, patients only see doctors periodically. This affects the early prescription rate until awareness grows. Further, insurance coverage has been only about 25% of covered lives until this month. Contracts with payers like United Healthcare have increased coverage to 50%. Cost was prohibitive for many patients in the early stage and that affects prescription rate. The prescription rate seen so far is normal in the launch of a drug like this. Negative factors are quickly improving. Things will look better soon.
View on StockTwits ↗
kyle@DrKyleBullish12h
$MIST i would think Dr David Brunk is what the average cardiologist is waiting for to open the floodgates....write a few scripts....after some positive feedback the floodgates open....
View on StockTwits ↗
Joe_Blow_88@Joe_BLow_88Bearish13h
$MIST Sell while still can. This ain't going nowhere but down for the near future.
View on StockTwits ↗
Joseph Greer@CashisKing_Bullish13h
$MIST wow..went from barish to bullish real fast lol the sentiment that is
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.